The lawsuit, spearheaded by the Rosen Law Firm, centers on claims that Insulet misled shareholders regarding the integrity of its production processes. According to the complaint, these undisclosed manufacturing deficiencies created a heightened risk of regulatory violations and potential product safety hazards. When these issues surfaced, shareholders allegedly suffered significant financial losses.

Investors holding losses exceeding $100,000 are being encouraged to step forward as potential lead plaintiffs. This representative role involves directing the litigation on behalf of the broader class of affected investors. While the case is currently active, no class has been certified, meaning shareholders are not yet represented by counsel unless they choose to retain one. Participation in a future recovery does not strictly require serving as a lead plaintiff, and investors retain the right to select their own legal representation.